R&D channel feed

ProKid­ney's stock shoots high­er af­ter mixed Phase 2 da­ta

4 hours ago

Ex­clu­sive: Start­up rais­es $45M for uni­ver­sal flu vac­cines made with mR­NA

5 hours ago
Startups

Sin­ga­pore­an biotech gets Chi­na thumbs-up for study of po­ten­tial­ly cu­ra­tive HBV cell ther­a­py

7 hours ago
China
Cell/Gene Tx

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

23 hours ago
Pharma
FDA+

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

Yesterday

Com­pro­mised drug lot im­pacts Jasper's chron­ic hives study, stock falls

Yesterday
Manufacturing

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

Yesterday

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

5 days ago
Pharma

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

5 days ago

4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans

5 days ago
People

Bris­tol My­er­s' Chi­na part­ner touts Phase 3 suc­cess for EGFRx­HER3 bis­pe­cif­ic ADC

6 days ago
China

Vyne stops en­rolling ear­ly-stage pso­ri­a­sis study fol­low­ing clin­i­cal hold lift, ear­ly da­ta

6 days ago

Ab­b­Vie cans oral ul­cer­a­tive col­i­tis drug from Lan­dos buy­out

6 days ago
Pharma

Sh­iono­gi, BioVer­sys team up on an­tibi­otics for lung dis­ease in deal worth up to $614M

6 days ago
Deals

PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill

6 days ago
Pharma
FDA+

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Last week
Cell/Gene Tx
In Focus

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Last week

Pro­tag­o­nist un­veils 'triple-G' obe­si­ty pill, but hu­man tri­als are near­ly a year away

Last week

Pfiz­er ends Phase 1b/2 tri­al for fi­nal Tril­li­um CD47 drug

Last week

Arc­turus claims Phase 2 suc­cess in first da­ta since shift to mR­NA ther­a­peu­tics, in­vestor re­ac­tion is mut­ed

Last week

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Last week
Pharma
FDA+

Ex­clu­sive: Khosla Ven­tures backs start­up sell­ing ‘ther­a­peu­tic plas­ma ex­change’ at longevi­ty clin­ics

Last week
Startups

Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

Last week

Mod­er­na's Phase 3 flu vac­cine ef­fi­ca­cy in line with com­peti­tors, tee­ing up new sub­mis­sions

Last week
Pharma
1234 Next page Last page
A service from the Financial Times